When was VivaVision Biotech founded?

VivaVision Biotech was founded in 2016 and raised its 1st funding round 5 years after it was founded.

Where is VivaVision Biotech located?

VivaVision Biotech is headquartered in Pudong, China.

Who is the current CEO of VivaVision Biotech?

Shen Wang of VivaVision Biotech. They have also founded 1 company.

Is VivaVision Biotech a funded company?

VivaVision Biotech is a funded company, having raised a total of $46M across 2 funding rounds to date. The company's 1st funding round was a $***** Series D round, raised on Apr 19, 2021.

When was the latest funding round of VivaVision Biotech?

VivaVision Biotech's latest funding was a $***** Series E round on Dec 15, 2023, with participation from 1 investor. Its primary sector is Ophthalmology. In China, the Ophthalmology sector has seen $31M in funding in 2026 to date.

Where does VivaVision Biotech rank among its competitors?

VivaVision Biotech ranks 10th amongst 53 active competitors, of which 17 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Biophytis, which secured $1.58M in Mar, 2026.

Who are the top competitors of VivaVision Biotech?

VivaVision Biotech's top competitors include Lineage Cell Therapeutics, Remegen and Stellular Bio. Among them, Biophytis secured the most recent funding round in March, 2026.

VivaVision Biotech - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutic solutions for treating multiple eye diseases. The company has developed a drug candidate VVN001 that helps in treating dry eye diseases such as e dryness, foreign body sensation, burning, itching, photophobia, jealousy, and blurred vision. Other products include VVN349 for atopic dermatitis, VVN460 for psoriasis, VVN539 for glaucoma, and many more.

Website: vivavisionbio.com
Email ID: *****@vivavisionbio.com

Key Metrics

Founded Year

2016

Location

Pudong, China

Stage

Series E

Total Funding

$46M in 2 rounds

Latest Funding Round

Series E, Dec 15, 2023, $*****

Investors

Sequoia Capital China & 7 more

Ranked

10^th among 53 active competitors

Similar Companies

Lineage Cell Therapeutics & 52 more

View VivaVision Biotech's full profile

VivaVision Biotech has raised a total funding of $46M over 2 rounds. Its first funding round was on Apr 19, 2021. Its latest funding round was a Series E round on Dec 15, 2023 for $*****. 1 investor participated in its latest round. VivaVision Biotech has 8 institutional investors.

Here is the list of recent funding rounds of VivaVision Biotech:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 15, 2023	3403164	Series E	6300799	1626394	5391052	2852393
Apr 19, 2021	3375386	Series D	3601490	9541804	Sequoia Capital China	Cenova & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of VivaVision Biotech's funding rounds and investors

The founders of VivaVision Biotech is Shen Wang. Shen Wang is the CEO of VivaVision Biotech.

Here are the details of VivaVision Biotech's key team members:

Shen Wang: Founder & CEO of VivaVision Biotech.

View details of VivaVision Biotech's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VivaVision Biotech include Lineage Cell Therapeutics, Remegen and Stellular Bio. Here is the list of Top 10 competitors of VivaVision Biotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	65/100
2nd	Remegen 2008, Yantai (China), Public	Developer of therapies for the treatment of cancer, autoimmune and eye diseases	$100M	Lilly Asia Ventures, Orbimed & 10 others	61/100
3rd	Stellular Bio 2014, Watertown (United States), Series A	Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells	$37.5M	Vivo Capital, Qiming & 5 others	59/100
4th	Biophytis 2006, Romainville (France), Public	Developer of drugs for neuromuscular and age-related diseases	$2.6M	Kreos Capital, Seventure Partners & 1 others	56/100
5th	Valitor 2010, Berkeley (United States), Series B	Developer of therapeutic proteins for multiple disease conditions	$38.2M	Morningside, ShangPharma Innovation & 9 others	55/100
6th	TearSolutions 2013, Charlottesville (United States), Series B	Topical therapeutics for the treatment of dry eye disease	$43M	Center for Innovative Technology, VTC Ventures ... & 5 others	54/100
7th	Azura Ophthalmics 1997, Tel Aviv (Israel), Series C	Developing therapies for meibomian gland dysfunction	$37.2M	Orbimed, Medical Research Commercialisation Fund ... & 4 others	53/100
8th	Retrotope 2006, Los Altos (United States), Acquired	Developer of therapeutics to treat neurodegenerative and ophthalmological diseases	$69.6M	SDL Ventures, Green Park & Golf Ventures ... & 12 others	53/100
9th	Marinomed 2006, Vienna (Austria), Public	Developer of drugs for immunology, allergy and infectious diseases	-	Invest, aws Mittelstandsfonds & 4 others	53/100
10th	VivaVision Biotech 2016, Pudong (China), Series E	Developer of therapeutic solutions for treating multiple eye diseases	$46M	Spinnotec, FengHe Group & 6 others	52/100